Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of ...

They are nonnegotiable for keeping pounds off long-term.

About half (53%) of Americans say they hear or read about Ozempic, Wegovy and similar drugs extremely or very often.

UTMB Health bariatric surgeon Dr. Sarah Samreen and obesity medicine specialist Dr. Andrea Stark sit down for an open, candid conversation about what's new, what's misunderstood, and what patients ...

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Higher protein intake may improve short-term hip bone strength during weight loss in older adults with overweight or obesity ...

Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with ...

Skye Bioscience has published 52-week data on its investigational obesity drug combination, linking the cocktail to 22.3% ...

A once-weekly injectable GIP/GLP-1 dual agonist conferred up to 22.5% weight loss at 48 weeks for adults with overweight or ...

The CDC said in a 2024 report that just 2-in-5 young adults are both weight-eligible and adequately active to join the ...

By Mrinalika Roy and Mariam Sunny Feb 4 (Reuters) - Eli Lilly forecast strong profit growth for 2026 on Wednesday on the back ...

Combining hormonal therapy and tirzepatide may lead to the greatest weight loss after menopause, new evidence suggests.